Merck & Co. Inc. has been fairly tight-lipped about its cholesteryl ester transfer protein (CETP) inhibitor anacetrapib for hypercholesterolemia while the 30,000-patient Phase III REVEAL clinical trial is ongoing, but the company said on Nov. 13 that the drug passed a recent futility test.
The REVEAL data monitoring committee (DMC) conducted a planned review of unblinded safety and efficacy data and said the trial...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
